CF
ESPR

Corebridge Financial’s Esperion Therapeutics ESPR Stock Holding History

Corebridge Financial’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-92,571
Closed -$133K – 901
2025
Q1 		$133K Sell
92,571
-1,373
-1% -$2.53K ﹤0.01% 2286
2024
Q4 		$207K Sell
93,944
-7,091
-7% -$16.5K ﹤0.01% 2161
2024
Q3 		$167K Sell
101,035
-623
-0.6% -$1.26K ﹤0.01% 2321
2024
Q2 		$227K Buy
+101,658
New +$239K ﹤0.01% 2116

Other funds holding ESPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
PCM
PenderFund Capital Management Vancouver, British Columbia, Canada $780M AUM 24.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Corebridge Financial's ESPR Position: Q2 2025 in Review

Corebridge Financial sold out of Esperion Therapeutics (ESPR) in Q2 2025, closing a stake of 92,571 shares — an estimated $133K sold.

Corebridge Financial first reported a position in ESPR in Q2 2024 and held it in 4 quarters. The position peaked at $227K in Q2 2024. 163 funds tracked by Wall St. Rank hold ESPR as of Q2 2025.

  • Corebridge Financial reported no remaining Esperion Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 92,571 Esperion Therapeutics shares in Q2 2025, an estimated $133K.
  • Corebridge Financial first reported a position in Esperion Therapeutics in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Esperion Therapeutics position peaked at $227K in Q2 2024.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.